Literature DB >> 18820712

GVHD after chemotherapy conditioning in allogeneic transplanted mice.

B Sadeghi1, N Aghdami, Z Hassan, M Forouzanfar, B Rozell, M Abedi-Valugerdi, M Hassan.   

Abstract

GVHD is a major complication in allogeneic SCT. Available GVHD models are mainly based on radiotherapy-conditioning and/or immune deficient mice. GVHD models based on chemotherapy-based regimens remain poorly studied, despite 50% of all transplantations being chemotherapy based. Our aim was to develop a GVHD model using chemotherapy as conditioning. Female BALB/c (H-2Kd) were conditioned with BU-CY and transplanted with 2 x 10(7) BM and 3 x 10(7) spleen cells from either C57BL/6 (H-2 Kb) mice (allogeneic setting) or from male BALB/c to serve as a control group for regimen-related toxicity and engraftment. GVHD manifestations and histopathological changes were evaluated. Chimerism and donor T cells presence in skin, intestine and liver were studied using FACS-, FISH analysis and immunohistochemistry. Allogeneic transplanted mice developed lethal GVHD starting from day+7 with both histological and clinical signs. Donor T cells accumulated in recipient skin and intestine with GVHD progression. BM-failure, apoptosis and T-lymphocyte infiltration into target organs were significantly higher in allogeneic when compared with the syngeneic group. No toxicity or GVHD signs were observed in the syngeneic setting. We report a mouse model of GVHD using BU-CY conditioning that represents the most common myeloablative-conditioning regimen in clinical SCT. This model can be utilized to study the role of conditioning on mechanisms underlying GVHD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18820712     DOI: 10.1038/bmt.2008.261

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  19 in total

1.  Dynamics of early histopathological changes in GVHD after busulphan/cyclophosphamide conditioning regimen.

Authors:  Sulaiman Al-Hashmi; Zuzana Hassan; Behnam Sadeghi; Björn Rozell; Moustapha Hassan
Journal:  Int J Clin Exp Pathol       Date:  2011-07-31

2.  Human Peripheral Blood Mononucleocyte Derived Myeloid Committed Progenitor Cells Mitigate H-ARS by Exosomal Paracrine Signal.

Authors:  Rishi Man Chugh; Payel Bhanja; Ximena Diaz Olea; Fang Tao; Kealan Schroeder; Ryan Zitter; Tanu Arora; Harsh Pathak; Bruce F Kimler; Andrew K Godwin; John M Perry; Subhrajit Saha
Journal:  Int J Mol Sci       Date:  2022-05-14       Impact factor: 6.208

3.  Using quantitative real-time PCR to determine donor cell engraftment in a competitive murine bone marrow transplantation model.

Authors:  Ningfei An; Yubin Kang
Journal:  J Vis Exp       Date:  2013-03-07       Impact factor: 1.355

4.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

5.  Neutrophil granulocytes recruited upon translocation of intestinal bacteria enhance graft-versus-host disease via tissue damage.

Authors:  Lukas Schwab; Luise Goroncy; Senthilnathan Palaniyandi; Sanjivan Gautam; Antigoni Triantafyllopoulou; Attila Mocsai; Wilfried Reichardt; Fridrik J Karlsson; Sabarinath V Radhakrishnan; Kathrin Hanke; Annette Schmitt-Graeff; Marina Freudenberg; Friederike D von Loewenich; Philipp Wolf; Franziska Leonhardt; Nicoleta Baxan; Dietmar Pfeifer; Oliver Schmah; Anne Schönle; Stefan F Martin; Roland Mertelsmann; Justus Duyster; Jürgen Finke; Marco Prinz; Philipp Henneke; Hans Häcker; Gerhard C Hildebrandt; Georg Häcker; Robert Zeiser
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440

Review 6.  Mouse models of graft-versus-host disease: advances and limitations.

Authors:  Mark A Schroeder; John F DiPersio
Journal:  Dis Model Mech       Date:  2011-05       Impact factor: 5.758

7.  Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning.

Authors:  Behnam Sadeghi; Suleiman Al-Hashmi; Zuzana Hassan; Bjorn Rozell; Hernan Concha; Carin Lundmark; Kjell-Olov Grönvik; Manuchehr Abedi-Valugerdi; Moustapha Hassan
Journal:  Clin Dev Immunol       Date:  2010-12-21

8.  Busulphan-cyclophosphamide cause endothelial injury, remodeling of resistance arteries and enhanced expression of endothelial nitric oxide synthase.

Authors:  Sulaiman Al-Hashmi; Piet J M Boels; Fahad Zadjali; Behnam Sadeghi; Johan Sällström; Kjell Hultenby; Zuzana Hassan; Anders Arner; Moustapha Hassan
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

9.  The role of programmed cell death ligand-1 (PD-L1/CD274) in the development of graft versus host disease.

Authors:  Heevy Al-Chaqmaqchi; Behnam Sadeghi; Manuchehr Abedi-Valugerdi; Sulaiman Al-Hashmi; Mona Fares; Raoul Kuiper; Joachim Lundahl; Moustapha Hassan; Ali Moshfegh
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

10.  Immune reconstitution and graft-versus-host reactions in rat models of allogeneic hematopoietic cell transplantation.

Authors:  Severin Zinöcker; Ralf Dressel; Xiao-Nong Wang; Anne M Dickinson; Bent Rolstad
Journal:  Front Immunol       Date:  2012-11-30       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.